Novo Nordisk Pharmatech showing recombinant insulin advantages at ESACT meeting

Koege, Denmark: – Novo Nordisk Pharmatech A/S, the leading worldwide supplier of high-quality insulin, will be a leading presence at the upcoming European Society for Animal Cell Technology (ESACT) meeting in Lausanne, Switzerland.

Novo Nordisk Pharmatech is a sponsor of the meeting and will also exhibit there at Booths 65-66 at Lausanne’s Swiss Tech Convention Center. Its display will focus on the increasingly influential role of recombinant insulin for innovative biologics and human vaccine production.

Serum-free growth

“We look forward to welcoming visitors to our stand to show them the advantages of growing their cells with insulin from Novo Nordisk Pharmatech,” said Marketing Manager Vanessa León.

“At Novo Nordisk Pharmatech we remain the leading worldwide supplier of recombinant insulin, which has become a key component in serum-free growth media for mammalian cells, approved by regulatory bodies worldwide, including FDA and EMA,” said Ms. León.

“Our products are manufactured to cGMP standards, allowing us to guarantee global regulatory compliance with extensive supporting documentation, consistent high quality and continuous availability on a secure global supply chain with high levels of service and support,” she added.

Influenza vaccine production

“We are able to tailor recombinant insulin to particular applications, such as specific Influenza production. This is increasingly important as the vaccine industry meets the challenges of producing large quantities of vaccines in a rapid and cost-effective way, while major changes to current bioprocesses are both difficult and very expensive to implement,” Vanessa León explained.

“Using HEK293 it has been demonstrated that an addition of recombinant human insulin to commercially available chemically defined media, can be used as a supplement to increase VCD and specific viral yield”, she noted.

About Novo Nordisk Pharmatech A/S

Novo Nordisk Pharmatech A/S was established in 1949 as FeF Chemicals, acquired by Novo Nordisk in 1986 and has been part of the pharmaceutical group since then. On 1 September 2015 the company’s name was changed to Novo Nordisk Pharmatech A/S. It is the leading worldwide supplier of recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (Quats) for the pharmaceutical, biopharmaceutical and personal care industries.

The company markets its diabetic care, haemophilia, growth hormone therapy, obesity, and hormone replacement therapy (HRT) products worldwide, with customers in more than 180 countries.

All Novo Nordisk Pharmatech products are manufactured to cGMP standards. The company has distinguished itself for global regulatory compliance, consistent high quality, extensive regulatory documentation, continuous availability, security of its global supply chain and high levels of service and support.

For Financial Year 2015, Novo Nordisk reported world sales totalling 107,927 million Danish kroner (DEK) with more than half of all sales recorded in North America.

About ESACT 2017

The European Society for Animal Cell Technology (ESACT) is dedicated to promoting knowledge sharing and best practice in cell biology. Its annual meeting has become an influential forum for those involved in bioprocessing, cell culture and fermentation, protein and gene expression worldwide.

The 25th annual meeting, ESACT 2017, is a four-day event that opens May 14 at the Swiss Tech Convention Center within the EPFL University campus at Lausanne, Switzerland.

The meeting is sponsored by Europe’s leading biotech companies, including Novo Nordisk Pharmatech, and will focus on cell technologies for innovative therapies with a programme designed to provide access to the latest innovation and advances in animal cell technology.

The event is organized by MCI Group with more information at: http://www.esact2017.com/